-
Marchés
-
Actions
Sustainable finance2025 Euronext ESG Trends ReportLire la suiteA data-driven snapshot of how Euronext-listed companies are advancing their Environmental, Social and Governance (ESG) practices.
-
Indices
Access the white paperInvesting in the future of Europe with innovative indicesLire la suiteThe first edition of the Euronext Index Outlook series with a particular focus on the European Strategic Autonomy Index.
-
ETF
The European market place for ETFsEuronext ETF EuropeLire la suiteInvestors benefit from a centralised market place that will not only bring transparency but also better pricing due to the grouping of liquidity.
- Fonds
-
Obligations
European Defence BondsGroupe BPCE lists the first bondLire la suiteFirst financial institution in Europe to issue a bond dedicated to the defence sector
- Produits Structurés
-
Dérivés
Where European Government Bonds Meet the FutureFixed Income derivativesLire la suiteTrade mini bond futures on main European government bonds
-
Marchandises
- Vue d'ensemble
- Vue d'ensemble
- Power Derivatives
- Milling Wheat derivatives
- Corn derivatives
- Spread contracts
- Rapeseed derivatives
- Durum Wheat derivatives
- Salmon derivatives
- Règlement livraison
- Spécifications et dispositions
- Commitments of Traders (CoT) report
- Commodity brokers
Building a sustainable and liquid power derivatives market.Euronext Nord Pool Power FuturesLire la suiteEuronext and Nord Pool, the European power exchange, announced the launch of a dedicated Nordic and Baltic power futures market.
-
Ressources
Designed to help students navigate the complexities of financial marketsEuronext Trading gameLire la suiteJoin the Euronext Trading Game and step into capital markets. Learn from today’s leaders, explore sustainable opportunities, and trade with confidence.
Company press releases
| Released | Company | Title | Industry | Topic |
|---|---|---|---|---|
| 29 Sep 2023 07:00 CEST |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics Initiates Phase 1/2a Trial of VB10.16 in First Line HPV16-Positive Head and Neck Cancer | 20103010 Biotechnology | Non-regulatory press releases |
| 27 Sep 2023 14:00 CEST |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics - presentation from Capital Markets Day in Oslo | 20103010 Biotechnology | Non-regulatory press releases |
| 25 Sep 2023 08:30 CEST |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics - Invitation to Capital Markets Day in Oslo on September 27, 2023 | 20103010 Biotechnology | Non-regulatory press releases |
| 20 Sep 2023 16:00 CEST |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics Announces Advances in Clinical Pipeline and Research | 20103010 Biotechnology | Non-regulatory press releases |
| 11 Sep 2023 10:36 CEST |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics to Present at H.C. Wainwright 25th Annual Global Investment Conference | 20103010 Biotechnology | Non-regulatory press releases |
| 07 Sep 2023 16:34 CEST |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics – Invitation to Capital Markets Day in New York on September 20, 2023 | 20103010 Biotechnology | Non-regulatory press releases |
| 05 Sep 2023 07:00 CEST |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics Announces FDA Approval of IND for VB-C-04, a Trial of VB10.16 in HPV16-Positive Cervical Cancer | 20103010 Biotechnology | Non-regulatory press releases |
| 23 Aug 2023 06:45 CEST |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics - Quarterly report Q2 2023 | 20103010 Biotechnology | Half yearly financial reports and audit reports/limited reviews |
| 17 Aug 2023 08:30 CEST |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics to announce financial results for the second quarter 2023 and host webcast presentation on August 23, 2023 | 20103010 Biotechnology | Non-regulatory press releases |
| 07 Jul 2023 17:01 CEST |
NYKODE THERAPEUTICS ASA | Grant of share options | 20103010 Biotechnology | Mandatory notification of trade primary insiders |
| 03 Jul 2023 20:54 CEST |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics – updated company presentation July 2023 | 20103010 Biotechnology | Non-regulatory press releases |
| 01 Jun 2023 06:45 CEST |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics Announces Expansion of Clinical Collaboration with Roche to Evaluate VB10.16 in Combination with anti-PD-L1 in the next trial in Advanced Cervical Cancer | 20103010 Biotechnology | Non-regulatory press releases |
| 30 May 2023 18:00 CEST |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics to Present at Jefferies Healthcare Conference | 20103010 Biotechnology | Non-regulatory press releases |
| 26 May 2023 16:46 CEST |
NYKODE THERAPEUTICS ASA | Grant of share options | 20103010 Biotechnology | Mandatory notification of trade primary insiders |
| 12 May 2023 07:00 CEST |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics - Quarterly report Q1 2023 | 20103010 Biotechnology | Half yearly financial reports and audit reports/limited reviews |
| 11 May 2023 11:10 CEST |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics ASA - Minutes of Annual General Meeting | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 10 May 2023 17:25 CEST |
NYKODE THERAPEUTICS ASA | Disclosure of voting rights at AGM | 20103010 Biotechnology | Major shareholding notifications |
| 08 May 2023 19:40 CEST |
NYKODE THERAPEUTICS ASA | Financial calendar | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 08 May 2023 19:40 CEST |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics to announce financial results for the first quarter 2023 and host webcast presentation on May 12, 2023 | 20103010 Biotechnology | Non-regulatory press releases |
| 20 Apr 2023 07:00 CEST |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics ASA - Notice of Annual General Meeting | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 19 Apr 2023 08:00 CEST |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics - Annual Report 2022 | 20103010 Biotechnology | Annual financial and audit Reports |
| 18 Apr 2023 16:44 CEST |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics announces positive final results from its Phase 2 trial of VB10.16 in combination with PD-L1 inhibitor atezolizumab in advanced cervical cancer | 20103010 Biotechnology | Inside information |
| 28 Feb 2023 07:00 CET |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics - Quarterly report 4Q 2022 | 20103010 Biotechnology | Half yearly financial reports and audit reports/limited reviews |
| 22 Feb 2023 13:00 CET |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics to announce financial results for the fourth quarter 2022 and host webcast presentation on February 28, 2023 | 20103010 Biotechnology | Non-regulatory press releases |
| 13 Feb 2023 08:11 CET |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics ASA – Flaggemelding Jan Haudemann-Andersen | 20103010 Biotechnology | Flagging |
| 10 Feb 2023 06:45 CET |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics Announces Collaboration with The GOG Foundation, Inc. to Conduct the VB-C-04 Trial in Advanced Cervical Cancer | 20103010 Biotechnology | Non-regulatory press releases |
| 07 Feb 2023 13:00 CET |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics to Present at SVB Securities Global Biopharma Conference | 20103010 Biotechnology | Non-regulatory press releases |
| 01 Feb 2023 13:31 CET |
NYKODE THERAPEUTICS ASA | Registration of new share capital | 20103010 Biotechnology | Total number of voting rights and capital |
| 25 Jan 2023 18:45 CET |
NYKODE THERAPEUTICS ASA | Exercise of warrants and related transactions by primary insiders | - | Mandatory notification of trade primary insiders |
| 09 Jan 2023 17:45 CET |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics - Presentation at the 41st Annual J.P. Morgan Healthcare Conference | 20103010 Biotechnology | Non-regulatory press releases |
| 30 Dec 2022 09:25 CET |
NYKODE THERAPEUTICS ASA | Financial calendar | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 23 Dec 2022 11:00 CET |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference | 20103010 Biotechnology | Non-regulatory press releases |
| 22 Dec 2022 12:43 CET |
NYKODE THERAPEUTICS ASA | Share capital increase from exercise of warrants | 20103010 Biotechnology | Total number of voting rights and capital |
| 20 Dec 2022 16:11 CET |
NYKODE THERAPEUTICS ASA | Registration of new share capital | 20103010 Biotechnology | Total number of voting rights and capital |
| 20 Dec 2022 06:45 CET |
NYKODE THERAPEUTICS ASA | Nykode announces expanded clinical development plan for its lead cancer vaccine VB10.16 in HPV16-positive cancers | 20103010 Biotechnology | Non-regulatory press releases |
| 19 Dec 2022 06:45 CET |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics and Richter-Helm BioLogics Announce Strategic Manufacturing Partnership | 20103010 Biotechnology | Non-regulatory press releases |
| 18 Dec 2022 22:45 CET |
NYKODE THERAPEUTICS ASA | Exercise of warrants by primary insider, transactions by a primary insider and a close associate, and disclosure of large shareholding | 20103010 Biotechnology | Mandatory notification of trade primary insiders |
| 06 Dec 2022 16:45 CET |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics Announces Clinical Collaboration with MSD to Evaluate VB10.16 in Combination With KEYTRUDA® (pembrolizumab) in Patients with HPV16-Positive Head and Neck Cancer | 20103010 Biotechnology | Non-regulatory press releases |